Introduction:
The pharmaceutical industry is evolving through a rapid digital transformation driven by increasing regulatory expectations, growing product complexity, and the need for greater transparency across manufacturing operations. Manufacturing Execution Systems have become a central pillar of this transformation, enabling real time process control, electronic batch recording, and robust data integrity across the product lifecycle. As a result, upgrades of established MES platforms are critical and compliance relevant transformations.
Within this context, upgrading from PAS X V2 to PAS X V3.3.2 represents far more than a cosmetic or technical system update. The new version introduces new system capabilities, different functional patterns, and tighter expectations on data integrity and electronic batch execution. At the same time, manufacturers cannot afford long verification cycles, duplicated effort, or uncertainty about whether migrated Master Batch Records (MBRs) are truly fit for use in the new environment.
Regulators and industry guidance consistently point toward risk based, proportionate approaches for computerized systems, emphasizing that compliance must be achieved efficiently, not through document inflation.
This project demonstrates how a structured, template driven verification approach for 64 MBRs and 2 GMBRs transformed a complex PAS-X migration into a controlled, scalable and economically sound process employed at a large, multinational science and technology company headquartered in Germany.
📃 Whitepaper: Standardized MBR Verification: Accelerating PAS-X Rollouts and Migration at Scale
By Zeynep Akgeyik, Junior Consultant | Pharma & BioTech Excellence
Pablo Cruz Gil, Consultant | Pharma & BioTech Excellence
Reach out to us at ReachUs@frontwell-solutions.com to request more info and/or an intro meeting.